NASHUA, N.H. and WILLIAMSVILLE, N.Y. and RALEIGH, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with Windsong Radiology Group, one of US Radiology Specialists, Inc.’s national network of premier providers of diagnostic imaging services located in Western New York. This relationship aims to implement iCAD’s ProFound AI Breast Health at Windsong Radiology center locations. The ...

NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service (Sa ...

NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service (S ...

NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at t ...

文章核心观点 - 近期AI相关股票表现强劲,但仍有许多小型AI公司股价未能充分反映其巨大潜力 [1] - 文章推荐了3家小型AI公司股票作为投资机会 Innodata (INOD) - 公司使用数据集训练AI模型,并帮助企业将AI应用于特定任务,同时还提供数字化医疗记录和营销平台 [2][3] - 公司业务专注于AI,拥有较强的技术实力和丰富的行业经验 [3] - 2023年第一季度收入同比增长41%至2650万美元,EBITDA(剔除特殊项目)增至380万美元 [4] - 机构投资者开始大量买入INOD股票 [5][6] Mitek Systems (MITK) - 公司提供利用AI的身份识别软件,主要应用于手机存款和欺诈检测 [7] - 公司正在开发语音认证技术,为未来发展带来新的增长空间 [8] - 2023财年收入和营业利润分别为1.726亿美元和2110万美元,同比增长 [8] - 公司股票估值较低,市盈率仅14.4倍 [8] iCAD (ICAD) - 公司利用AI技术更准确地检测乳腺癌 [9] - 公司加强销售团队建设,并拓展海外市场,2023年第一季度收入同比增长14% [9][10][11] - 公司当前市值仅4300万美元,远低于其长期潜力 [11]

财务数据和关键指标变化 - 第一季度收入为5百万美元,同比增长14% [61] - 第一季度产品收入为3.1百万美元,同比增长26% [61] - 第一季度毛利率为83%,同比提升1个百分点 [62] - 第一季度GAAP净亏损为1.2百万美元,每股亏损0.05美元,同比亏损减少 [63] - 第一季度非GAAP调整后EBITDA亏损为1.1百万美元,同比亏损减少1.3百万美元 [63] - 截至3月31日,公司现金及现金等价物为20.3百万美元 [64] 各条业务线数据和关键指标变化 - 公司正在向订阅收入模式转型,第一季度订阅收入ARR为1.9百万美元,环比增长 [66][67][68] - 第一季度共签订76个永久许可和16个订阅订单 [69] 各个市场数据和关键指标变化 - 公司在美国、欧洲、中东、以色列等多个国家和地区实现新客户签约和产品部署 [15][20][21][22][23][24] - 公司产品在法国、比利时和以色列等国家获得电视媒体报道 [25] 公司战略和发展方向及行业竞争 - 公司正在实施三阶段转型战略,第三阶段聚焦于扩展现有解决方案到关键客户和新市场 [10][11][12][13][14] - 公司加强了销售团队,增加了销售人员,并调整了销售策略和商业模式 [13][14] - 公司推出了ProFound Cloud云平台,提供软件即服务模式,提升了产品的可访问性和可扩展性 [48][49][50][51][52][53] - 公司与RAD-AID国际组织合作,将ProFound AI解决方案部署到圭亚那,提高当地医疗机构的乳腺癌筛查能力 [37][38][39][40][41] 管理层对经营环境和未来前景的评论 - 管理层对公司的发展前景保持乐观,认为公司有能力为股东创造价值 [105] - 管理层表示,公司的技术创新和产品升级不断推进,有助于提高乳腺癌筛查的准确性和效率 [44][45][46][47] - 管理层认为,公司正在采取有效措施提升销售业绩,包括加强销售团队、优化商业模式等 [10][11][12][13][14] 问答环节重要的提问和回答 问题1 **Per Ostlund 提问** 询问公司的销售团队扩充计划以及新的营销和商业模式的具体情况 [72][73] **Dana Brown 回答** 公司销售团队规模已基本稳定,未来可能会根据新业务和现有客户拓展情况进行适当调整 [73] 公司已建立了更加系统和可衡量的营销线索生成机制,并优化了定价、销售策略等商业模式 [74][75][76][77][78][79][80][81][82] 问题2 **Yale Jen 提问** 询问公司的云平台产品是否已经商业化,以及未来的发展计划 [97][98] **Dana Brown 回答** 公司的ProFound Cloud云平台已经商业化,销售团队正在积极推广,并已经获得首个客户 [98] 公司未来将继续推动云平台的销售,并通过云模式提升产品的可访问性和可扩展性 [48][49][50][51][52][53] 问题3 **Yale Jen 提问** 询问公司业务的季节性特征是否仍然存在 [99] **Dana Brown 回答** 公司业务仍然存在一定的季节性,主要受客户预算周期的影响,第四季度通常是销售旺季 [100][101][102][103]

Exhibit 99.1 iCAD Reports Financial Results for First Quarter Ended March 31, 2024 NASHUA, N.H. – May 15, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): ● Total ARR was $9.0 million, up 10% ● Total revenues were $5.0 million, up 14% ● ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09341 iCAD, Inc. (Exact name of registrant as specified in its charter) Delaware 02-0377419 (State or other ju ...

NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https://www.webcaster4.com/Webcast/Page/2879/50453 A ...

NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https://www.webcaster4.com/Webcast/Page/2879/50453 ...